Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

被引：0
|
作者：
Hiroshi Yokouchi
Koichi Yamazaki
Ichiro Kinoshita
Jun Konishi
Hajime Asahina
Noriaki Sukoh
Masao Harada
Kenji Akie
Shigeaki Ogura
Takashi Ishida
Mitsuru Munakata
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Masaharu Nishimura
机构：
[1] Hokkaido University School of Medicine,First Department of Medicine
[2] Hokkaido University Graduate School of Medicine,Department of Medical Oncology
[3] National Hospital Organization Hokkaido Cancer Center,Department of Respiratory Medicine
[4] Sapporo City General Hospital,Department of Respiratory Disease
[5] Fukushima Medical University,Department of Pulmonary Medicine
[6] KKR Sapporo Medical Center,Department of Medical Oncology
[7] Hokkaido Lung Cancer Clinical Research Group,undefined
来源：
BMC Cancer | / 7卷
关键词：
Overall Survival; Epidermal Growth Factor Receptor; Bone Metastasis; Gefitinib; Epidermal Growth Factor Receptor Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
    Tomizawa, Yoshio
    Fujita, Yuka
    Tamura, Atsuhisa
    Shirai, Masahiro
    Shibata, Satoshi
    Kawabata, Tsutomu
    Shibayama, Takuo
    Fukai, Shimao
    Kawahra, Masaaki
    Saito, Ryusei
    LUNG CANCER, 2010, 68 (02) : 269 - 272
  • [12] Clinical Characteristics of Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
    Lee, Kye Young
    Kim, Hee Joung
    Kim, Young-Chul
    Kim, Kyu-Sik
    Oh, In-Jae
    Ban, Hee Jung
    Lee, Sung Yong
    Jang, Tae Won
    Shin, Kyeong-Cheol
    Lee, Gwan Ho
    Lce, Jae Chol
    Ryu, Jeong-Seon
    Jang, Seung Hoon
    Lee, Jeong Eun
    Kim, Sun Young
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S396 - S397
  • [13] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [14] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [15] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [16] Gefitinib (Iressa) trials in non-small cell lung cancer
    Johnson, DH
    LUNG CANCER, 2003, 41 : S23 - S28
  • [17] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [18] Gefitinib in Non Small Cell Lung Cancer
    Costanzo, Raffaele
    Piccirillo, Maria Carmela
    Sandomenico, Claudia
    Carillio, Guido
    Montanino, Agnese
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    De Feo, Gianfranco
    Di Maio, Massimo
    Rocco, Gaetano
    Normanno, Nicola
    Perrone, Francesco
    Morabito, Alessandro
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
  • [19] Steatocystoma multiplex as initial impression of non-small cell lung cancer with complete response to gefitinib
    Tsai, Ming-Hung
    Hsiao, Yu-Ping
    Lin, Wea-Lung
    Tseng, Szu-Wen
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (01) : E5 - E9
  • [20] Basic Clinical Parameters Predict Gefitinib Efficacy in Non-small Cell Lung Cancer
    Pircher, Andreas
    Ulsperger, Ernst
    Hack, Rene
    Jamnig, Herbert
    Pall, Georg
    Zelger, Bettina
    Sterlacci, William
    Hilbe, Wolfgang
    Fiegl, Michael
    ANTICANCER RESEARCH, 2011, 31 (09) : 2949 - 2955
12345